Skip to main content

Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway.

Author(s): Bugaj, Lukasz J; Sabnis, Amit J; Mitchell, Amir; Garbarino, JE; Toettcher, Jared E; et al

To refer to this page use:
Abstract: The Ras-Erk (extracellular signal-regulated kinase) pathway encodes information in its dynamics; the duration and frequency of Erk activity can specify distinct cell fates. To enable dynamic encoding, temporal information must be accurately transmitted from the plasma membrane to the nucleus. We used optogenetic profiling to show that both oncogenic B-Raf mutations and B-Raf inhibitors can cause corruption of this transmission, so that short pulses of input Ras activity are distorted into abnormally long Erk outputs. These changes can reshape downstream transcription and cell fates, resulting in improper decisions to proliferate. These findings illustrate how altered dynamic signal transmission properties, and not just constitutively increased signaling, can contribute to cell proliferation and perhaps cancer, and how optogenetic profiling can dissect mechanisms of signaling dysfunction in disease.
Publication Date: 31-Aug-2018
Citation: Bugaj, LJ, Sabnis, AJ, Mitchell, A, Garbarino, JE, Toettcher, JE, Bivona, TG, Lim, WA. (2018). Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway.. Science (New York, N.Y.), 361 (6405), 10.1126/science.aao3048
DOI: doi:10.1126/science.aao3048
ISSN: 0036-8075
EISSN: 1095-9203
Pages: eaao3048 - eaao3048
Language: eng
Type of Material: Journal Article
Journal/Proceeding Title: Science
Version: Author's manuscript

Items in OAR@Princeton are protected by copyright, with all rights reserved, unless otherwise indicated.